Last reviewed · How we verify
BDP/FF/GB
BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.
BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways. Used for Chronic obstructive pulmonary disease (COPD), Asthma (potential indication under investigation).
At a glance
| Generic name | BDP/FF/GB |
|---|---|
| Also known as | CHF 5993 pMDI 100/6/12.5 mcg |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone dipropionate (BDP) is a corticosteroid that suppresses airway inflammation. Formoterol fumarate (FF) is a long-acting beta-2 agonist that provides bronchodilation. Glycopyrronium bromide (GB) is a long-acting muscarinic antagonist that provides additional bronchodilation via anticholinergic mechanisms. The combination addresses multiple pathophysiologic mechanisms in obstructive airway disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (potential indication under investigation)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Dysphonia
Key clinical trials
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (PHASE3)
- PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDP/FF/GB CI brief — competitive landscape report
- BDP/FF/GB updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI